Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma
N/A
15 Years
N/A
15 Years
N/A
Not Enrolling
Both
NK/T Cell Lymphoma
Both
NK/T Cell Lymphoma
Trial Information
Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma
Inclusion Criteria:
- NK/T cell lymphoma
- relapse or refractory disease
- gemcitabine containing treatment
Exclusion Criteria:
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
Overall response rate
Outcome Time Frame:
2012-May
Safety Issue:
No
Authority:
Korea: Institutional Review Board
Study ID:
2012-07-043
NCT ID:
NCT01660568
Start Date:
August 2012
Completion Date:
January 2013
Related Keywords:
- NK/T Cell Lymphoma
- Lymphoma
- Lymphoma, T-Cell
Name | Location |
|---|
